Skip to content

Whole body vibration for osteoporosis: Shaking up treatment options.

A semi-blind, block-randomised clinical trial investigating the effects of low-intensity whole body vibration (WBV) with or without exercise on risk factors for hip fracture in postmenopausal women.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000848505
Acronym
VIBMOR
Enrollment
252
Registered
2015-08-14
Start date
2018-06-01
Completion date
2021-05-05
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

For the many individuals with established osteoporosis who will not, or cannot take medication there are currently no recommended therapeutic alternatives. Calcium and vitamin D are vital but insufficient therapies and are similarly limited by poor patient compliance. Recent evidence suggests high intensity exercise is an effective stimulus for bone. Whole body vibration (WBV) can also be anabolic to the musculoskeletal system. Early research has shown that WBV is a simple, passive therapy with greater appeal to the target population than exercise or drugs. This trial will be the first to use rigorous methods to examine the effects of WBV alone, and in combination with high-intensity exercise, in participants on and off bone medications, to improve risk factors for hip fracture (bone density, balance and muscle strength).

Interventions

Arm 1. WBV: Participants will stand on the 30 Hz WBV device installed in their home for 10-minutes 5 days per week for 9 months. Compliance is recorded by the device. Arm 2. HiRIT: Participants will attend Griffith University for a 30-minute high intensity resistance and impact training (HiRIT) session, supervised by a trained exercise physiologist or exercise scientist, twice per week for 9 months. A participant diary will be completed every session. Arm 3. HiRIT + WBV: Participants will stan

Arm 1. WBV: Participants will stand on the 30 Hz WBV device installed in their home for 10-minutes 5 days per week for 9 months. Compliance is recorded by the device. Arm 2. HiRIT: Participants will attend Griffith University for a 30-minute high intensity resistance and impact training (HiRIT) session, supervised by a trained exercise physiologist or exercise scientist, twice per week for 9 months. A participant diary will be completed every session. Arm 3. HiRIT + WBV: Participants will stand on the WBV device installed in their home for 10-minutes 5 days per week for 9 months, and attend Griffith University for a 30-minute high intensity resistance and impact training (HiRIT) session, supervised by a trained exercise physiologist or exercise scientist, twice per week for 9 months. Compliance is recorded by the device, and a participant diary will be completed every session.

Sponsors

Griffith University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1) women 2) at least 5 year post-menopause 3) with low bone mineral density (hip BMD t score less than or equal to -1.0) 4) with or without anti-absorptive osteoporosis drug with no plans to change therapy for the next 21 months 5) willing and able to attend twice-weekly on-campus training and 5 times a week in-home WBV 6) weigh less than 125 kg

Exclusion criteria

1) Fraility 2) Inability to stand unaided 3) Cognitive impairment 4) Moderate to high levels of bone-relevant physical activity in previous 8 months 5) Regular use of vibration plate in last 8 months 6) Malignancy 6) On the following medications, Strontium ranelate or anabolic osteoporosis medication e.g. parathyroid hormone, corticosteroids, thyroxine, thiazide or anti-viral agents 7) Have conditions known to influence bone health e.g. thyrotoxicosis or hyperthyroidism, Paget's disease, renal diseases and diabetes, or to prevent engaging in HiRIT without risk.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026